Skip to main content
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Main navigation - Mobile
New Findings from the Veeva 2018 Unified Clinical Operations Survey
BMS, AbbVie eye new Empliciti use after phase 2 combo win
Monday, June 18, 2018
With impressive new survival data in hand, Bristol-Myers Squibb and AbbVie could land a new indication for Empliciti.
AstraZeneca's Fasenra fails second COPD trial
Wednesday, May 30, 2018
AstraZeneca’s hopes for expanding severe asthma drug Fasenra into COPD are officially lost.
J&J's Darzalex ambitions take a hit with scrapped I-O trials
Tuesday, May 29, 2018
Drugmakers have hoped that pairing their cancer drugs with I-O treatments would improve benefits. Not for Genmab and J&J.
AstraZeneca's Fasenra ambitions take a hit with failed COPD test
Friday, May 11, 2018
AZ was hoping its next-gen COPD med Fasenra could help it keep pace with GlaxoSmithKline, but the drug just failed to beat placebo in a phase 3 study.
RBM: The Missing Link Bringing Drugs to Market Efficiently
Roche hits pause on Tecentriq-Cotellic trial enrollment
Wednesday, April 11, 2018
Roche may have just hit a snag in its bid to push a combination of Tecentriq and Cotellic into metastatic colorectal cancer.
FiercePharmaAsia—Takeda, WuXi AppTec and Aslan
Friday, March 30, 2018
Takeda weighs a $52 billion Shire bid, WuXi gets approval for a $900M-plus Shanghai IPO, Aslan aims to raise $86 million through an IPO on Nasdaq.
Roche's Tecentriq posts its second lung cancer win this week
Monday, March 26, 2018
Roche is back with more survival data for its Tecentriq-Avastin cocktail—and it’s more important survival data, too.
Glaxo aims to lure patients from Novartis' Xolair
Monday, March 5, 2018
GlaxoSmithKline is taking direct aim at severe asthma challenger Xolair from Novartis.